Precise identification of viral–host integration events in HPV-positive cervical cancers by targeted long-read sequencing Journal Article


Authors: Parida, P.; Mukherjee, N.; Singh, A.; Lewis, S.; Sharan, K.; Mallya, S.; Singh, A.; Das, S. S.; Rao, M.; Higginson, D. S.; Sabarinathan, R.; Damerla, R. R.
Article Title: Precise identification of viral–host integration events in HPV-positive cervical cancers by targeted long-read sequencing
Abstract: Human papillomaviral (HPV) integrations into host human genome, a frequently observed event in HPV associated cervical cancer, are currently mapped through expensive Whole Genome sequencing (WGS) or RNA sequencing (RNA-seq) methodologies. This study aims to develop a targeted sequencing assay to determine HPV integrations in cervical tumors without the need for WGS or RNA-seq. We employed a library preparation strategy using tiled single primers that bind to HPV genome as a template and possibly extend HPV sequences into adjacent host human genomic sequences resulting in HPV and human chimeric sequences. Using this strategy, we sequenced known HPV integrations in HPV18 positive HeLa and HPV16 positive SiHa cell lines. We further used this method to detect HPV integration sites in four HPV-positive cervical cancer patients and confirmed these integration breakpoints by WGS and Sanger sequencing. Functional impact of HPV integrations was explored through differentially expressed genes within or near topologically associating domain (TAD) boundaries, possibly disrupted by respective integration events in these patients. We found ZFP36L1, CPA3, CPB1 and CXCL8 as some of the differentially expressed genes within disrupted TADs, which are known cancer associated genes. Our approach also reduced the cost of HPV integration detection by 90 % compared to WGS while also minimizing sequencing data volume. We believe that this method captures HPV integrations at significantly reduced costs and lesser sequencing data volume leading to better understanding of disease progression and monitoring cancer treatment. © 2025 The Authors
Keywords: adult; controlled study; human tissue; gene sequence; human cell; cancer growth; nonhuman; validation process; cancer patient; gene; gene expression; interleukin 8; patient monitoring; cancer therapy; chimera; cost control; uterine cervix cancer; virus genome; cervical cancer; wart virus; virus cell interaction; human papillomavirus type 16; human papillomavirus type 18; clinical significance; sanger sequencing; human; female; article; whole genome sequencing; rna sequencing; hela cell line; differential gene expression; nanopore sequencing; hpv integration; cpa3 gene; cpb1 gene; cxcl8 gene; siha cell line; zfp36l1 gene
Journal Title: Tumour Virus Research
Volume: 20
ISSN: 2666-6790
Publisher: Elsevier, Inc.  
Date Published: 2025-12-01
Start Page: 200325
Language: English
DOI: 10.1016/j.tvr.2025.200325
PROVIDER: scopus
PMCID: PMC12301824
PUBMED: 40683617
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors